Research programme: oncolytic virus therapeutics - Neotropix

Drug Profile

Research programme: oncolytic virus therapeutics - Neotropix

Alternative Names: NTX-100; NTX-250; NTX-400; NTX-420; NTX-500; NTX-800

Latest Information Update: 16 Jun 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neotropix
  • Class Oncolytic viruses
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jun 2011 Research programme: oncolytic virus therapeutics - Neotropix is available for licensing. http://www.neotropix.com
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 05 Sep 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top